Andere Sprachen Otsuka Holdings Co., Ltd.

Aktien

A1C9KC

JP3188220002

4578

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 26.04.2024			% 5 Tage	% 1. Jan.
6 370 ^JPY	+1,56 %		+2,97 %	+20,44 %

09.04.	H. Lundbeck und Otsuka Pharmaceutical beantragen US FDA-Zulassung für PTSD-Kombinationstherapie	MT
27.03.	EU-Kommission gibt grünes Licht für Abilify Maintena von Lundbeck und Otsuka als Erhaltungstherapie bei Schizophrenie	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09.04.
Bourses asiatiques: Tokyo mi-figue, mi-raisin, Hong Kong confiante	02.04.
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	29.03.
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27.03.
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18.03.
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	07.03.
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	26.02.
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16.02.
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	16.02.
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	16.02.
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	14.02.
Otsuka Holdings Lowers 2023 Profit Outlook	13.02.
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range	13.02.
Japan's Nikkei soars to 34-year high on chip shares, earnings	13.02.
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint	13.02.
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	13.02.
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023	13.02.
Otsuka Group Selected for CDP Climate Change a List for a Second Consecutive Year	08.02.
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	22.01.
Marchés mondiaux: l'Europe dans le vert avant l'inflation américaine	11.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Otsuka Holdings Co., Ltd.

Aktien

A1C9KC

JP3188220002

4578

Andere Sprachen

Filter